Gene Mutation Provides Resistance to HIV Infection

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 9
Volume 5
Issue 9

NEW YORK--Scientists at the Aaron Diamond AIDS Research Center appear to have solved one of the long-standing enigmas of HIV infection--why some people remain uninfected even after repeated exposures to the virus. The answer lies in the genes, and in basic research published only a few months earlier.

NEW YORK--Scientists at the Aaron Diamond AIDS Research Centerappear to have solved one of the long-standing enigmas of HIVinfection--why some people remain uninfected even after repeatedexposures to the virus. The answer lies in the genes, and in basicresearch published only a few months earlier.

Studies of two homosexual men who have avoided infection sincethe start of the AIDS epidemic, despite having HIV-positive partners,uncovered a genetic mutation that appears to protect against infectionwith the virus. Both men were found to have two mutant copiesof the CCR5 gene (also known as CKR-5, or chemokine receptor-5),whose discovery was reported by five different groups in Junein a flurry of papers in Nature, Science, and Cell.

The CCR5 gene produces a protein receptor that allows HIV entryinto human immune cells. The two men with the mutant gene didnot have the receptor, Dr. Nathan R. Landau and his colleaguesreported in the journal Cell (August 9, 1996).

Other work suggests that as many as 1% of whites of Western Europeandescent may have the gene mutation, and up to 20% of whites mayhave one copy of the defective gene. Even one copy may have aprotective role, either in lowering the risk of infection or indelaying progression of HIV after infection.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.